Peptide library / Digestive & weight / Pramlintide
Pramlintide
A synthetic amylin analog injected at mealtimes alongside insulin.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Lower blood sugar after meals in type 1 and type 2 diabetes using insulinFDA approved
- Modest weight loss in diabetesLarge trials
How it is thought to work
Pramlintide mimics amylin, a hormone made with insulin, and slows stomach emptying, blunts glucagon and increases fullness after meals.
What the evidence shows
Trials showed small reductions in HbA1c and modest weight loss when added to mealtime insulin.
Safety and unknowns
Severe hypoglycemia can occur when it is combined with insulin, so insulin doses must be reduced when starting. The label carries a boxed warning for this risk.
Regulatory status
FDA-approved as Symlin in 2005.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Digestive & weight
PYY 3-36
Wellness and performanceA gut hormone released after eating that reduces hunger, studied for obesity but never approved.
Retatrutide
In clinical trialsAn investigational once-weekly triple agonist of the GIP, GLP-1 and glucagon receptors from Eli Lilly.
PN-943
In clinical trialsAn investigational oral peptide that stays in the gut and blocks immune cells from entering the bowel wall.
General information, not medical advice. Do not buy or inject unregulated peptides.